Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Pharmacological cognitive enhancement in schizophrenia.

Harvey PD.

Neuropsychol Rev. 2009 Sep;19(3):324-35. doi: 10.1007/s11065-009-9103-4. Epub 2009 Jun 9. Review.

PMID:
19507034
2.

On the trail of a cognitive enhancer for the treatment of schizophrenia.

Stip E, Chouinard S, Boulay LJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):219-32. Epub 2005 Jan 16. Review.

PMID:
15694228
3.

Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.

Sumiyoshi T, Bubenikova-Valesova V, Horacek J, Bert B.

Adv Ther. 2008 Oct;25(10):1037-56. doi: 10.1007/s12325-008-0102-2. Review.

PMID:
18839076
4.

The neurobiology of cognition in schizophrenia.

Tamminga CA.

J Clin Psychiatry. 2006;67 Suppl 9:9-13; discussion 36-42. Review.

5.

Pharmacological strategies for enhancing cognition in schizophrenia.

Barch DM.

Curr Top Behav Neurosci. 2010;4:43-96. Review.

PMID:
21312397
6.

[Treatment of cognitive deficits in schizophrenia. Part 2: Pharmacological strategies].

Roesch-Ely D, Pfueller U, Mundt C, Müller U, Weisbrod M.

Nervenarzt. 2010 May;81(5):564-76. doi: 10.1007/s00115-009-2919-6. Review. German.

PMID:
20195567
7.

The neurobiology of cognition in schizophrenia.

Tamminga CA.

J Clin Psychiatry. 2006 Sep;67(9):e11. Review.

8.

Drug targets for cognitive enhancement in neuropsychiatric disorders.

Wallace TL, Ballard TM, Pouzet B, Riedel WJ, Wettstein JG.

Pharmacol Biochem Behav. 2011 Aug;99(2):130-45. doi: 10.1016/j.pbb.2011.03.022. Epub 2011 Apr 1. Review.

PMID:
21463652
9.

Treatment of cognitive deficits in schizophrenia.

Bowie CR, Harvey PD.

Curr Opin Investig Drugs. 2006 Jul;7(7):608-13. Review.

PMID:
16869112
10.

Executive functioning component mechanisms and schizophrenia.

Kerns JG, Nuechterlein KH, Braver TS, Barch DM.

Biol Psychiatry. 2008 Jul 1;64(1):26-33. doi: 10.1016/j.biopsych.2008.04.027.

PMID:
18549874
12.

Impact on cognition of the use of antipsychotics.

Sharma T.

Curr Med Res Opin. 2002;18 Suppl 3:s13-7. Review.

PMID:
12418607
13.

Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.

Terry AV Jr, Buccafusco JJ, Wilson C.

Behav Brain Res. 2008 Dec 16;195(1):30-8. doi: 10.1016/j.bbr.2007.12.006. Epub 2008 Feb 1. Review.

PMID:
18241938
14.

Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?

Meltzer HY, Sumiyoshi T.

Behav Brain Res. 2008 Dec 16;195(1):98-102. doi: 10.1016/j.bbr.2008.05.016. Epub 2008 May 29. Review.

PMID:
18707769
15.

Assessing and treating cognitive impairment in schizophrenia: current and future.

Lin CY, Tsai GE, Lane HY.

Curr Pharm Des. 2014;20(32):5127-38. Review.

PMID:
24410565
16.

Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

Houthoofd SA, Morrens M, Sabbe BG.

Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Review.

PMID:
18840365
17.

Neuropharmacological aspects of cognitive neurorehabilitation in epilepsy.

Mula M, Trimble MR.

Behav Neurol. 2006;17(1):69-75. Review.

PMID:
16720961
18.

Cognitive effects of second-generation antipsychotics: current insights into neurochemical mechanisms.

Fumagalli F, Frasca A, Racagni G, Riva MA.

CNS Drugs. 2009;23(7):603-14. doi: 10.2165/00023210-200923070-00005. Review.

PMID:
19552487
19.

Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease.

Robbins TW, McAlonan G, Muir JL, Everitt BJ.

Behav Brain Res. 1997 Feb;83(1-2):15-23. Review.

PMID:
9062655
20.

Oral cholinesterase inhibitor add-on therapy for cognitive enhancement in schizophrenia: a quantitative systematic review, Part I.

Chouinard S, Sepehry AA, Stip E.

Clin Neuropharmacol. 2007 May-Jun;30(3):169-82. Review.

PMID:
17545751

Supplemental Content

Support Center